Chinook Therapeutics, Inc.
Industry Group: Pharmaceuticals
Country/Region: United States of America
Identifier: -
Chinook Therapeutics Inc is a clinical-stage biotechnology company. The products of the company are focused on rare, severe chronic kidney disorders. The clinical program is atrasentan, a potent and selective endothelin A receptor antagonist and currently conducting the phase 3 ALIGN trial of atrasentan for IgA nephropathy (IgAN) and the phase 2 AFFINITY basket trial for proteinuric glomerular diseases. The second product candidate, BION-1301, is an anti-APRIL monoclonal antibody and the third product candidate is CHK-336, an oral small-molecule LDHA inhibitor for the treatment of primary and idiopathic hyperoxaluria. It is incorporated in Delaware and is headquartered in Seattle, Washington.
ESG Risk Rating
Ranking
Industry Group (1st = lowest risk)
Pharmaceuticals 713 out of 851
Universe
Global Universe 13088 out of 15094
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. They are not directed to, or intended for distribution to or use by India-based clients or users and their distribution to Indian resident individuals or entities is not permitted. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source. For referencing Sustainalytics please consult the Company Guide.
Industry Comparison
| Company | ESG Risk Rating | Industry Rank |
|---|---|---|
| Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. |
36.1
High
|
707 out of 851 |
| Chinook Therapeutics, Inc. |
36.3
High
|
713 out of 851 |
| Gritstone bio, Inc. |
36.5
High
|
723 out of 851 |
| Mallinckrodt Plc |
39.4
High
|
807 out of 851 |
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Management
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.